# Laboratory-developed tests and in vitro diagnostics: A regulatory overview for anatomic pathology

**Authors:** Jonathan R Genzen, Lauren J Miller, Anton V Rets, Kajsa E Affolter

PMC · DOI: 10.1093/ajcp/aqae181 · American Journal of Clinical Pathology · 2025-02-06

## TL;DR

This paper explains new FDA regulations for lab-developed tests and existing rules for in vitro diagnostics in the context of anatomic pathology.

## Contribution

It provides a regulatory overview of the 2024 FDA Final Rule and its implications for anatomic pathology.

## Key findings

- The Final Rule introduces enforcement discretion policies for certain lab-developed tests.
- Existing regulations for Class I, II, and III medical devices are reviewed in the context of anatomic pathology.
- Pathologists and lab supervisors should understand these regulations to ensure compliance.

## Abstract

The US Food and Drug Administration’s Final Rule on laboratory-developed tests was published on May 6, 2024. The objective of this article is to explain the Final Rule and existing in vitro diagnostic regulations in the context of anatomic pathology.

The Final Rule, US in vitro diagnostic regulations, guidance documents, government publications, websites, news articles, and publications were reviewed, with sources including the Federal Register, the Code of Federal Regulations, the US Code, statutory text, PubMed, and Internet resources. Regulations applicable to device classifications and product codes relevant to anatomic pathology were highlighted.

The Final Rule outlines requirements and enforcement discretion policies applicable to anatomic pathology, including the Food and Drug Administration’s targeted enforcement discretion for “1976-type” laboratory-developed tests and partial enforcement discretion with laboratory-developed tests for unmet needs. Existing regulations, including the classification and requirements applicable to Class I, II, and III medical devices, are reviewed, including those for immunohistochemistry kits and reagents, analyte specific reagents, and research use only reagents and equipment.

Pathologists, laboratory directors, managers, and supervisors responsible for anatomic pathology testing should be familiar with existing regulations and the Final Rule to ensure compliance with federal laws and regulations.

## Full-text entities

- **Genes:** PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, FOLR1 (folate receptor alpha) [NCBI Gene 2348] {aka FBP, FOLR, FR-alpha, FRalpha, NCFTD}
- **Diseases:** HIV (MESH:D015658), tuberculosis (MESH:D014376), GIST (MESH:D046152), II (MESH:C537730), neoplasm (MESH:D009369), chronic lymphocytic leukemia (MESH:D015451), DIAGNOSTICS (MESH:D005119), hematologic malignancies (MESH:D019337), chromosomal abnormalities (MESH:D002869), LDTs (MESH:D007757)
- **Chemicals:** LDT (-), formalin (MESH:D005557), iron (MESH:D007501), paraffin (MESH:D010232), imatinib (MESH:D000068877)
- **Species:** Homo sapiens (human, species) [taxon 9606], Treponema pallidum (species) [taxon 160], Cytomegalovirus (genus) [taxon 10358]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12086060/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12086060/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12086060/full.md

---
Source: https://tomesphere.com/paper/PMC12086060